Literature DB >> 17099344

Drooling.

Devyani Lal1, Andrew J Hotaling.   

Abstract

PURPOSE OF REVIEW: Drooling is the involuntary spillage of saliva from the mouth. It is a major morbidity associated with cerebral palsy and other neurodegenerative disorders. The consequences of drooling are not restricted to medical issues but can cause major social handicaps. Severe psycho-social consequences, such as social stigmatization and emotional devastation for the patients and their families, may result. This paper reviews recent developments in the management of drooling. RECENT
FINDINGS: Recent publications report encouraging results with botulinum toxin A. Several surgeons report on their long-term results. Reviews analyze anticholinergic drugs, surgical options, biofeedback, behavioral and speech therapy, and a multidisciplinary team approach.
SUMMARY: A team approach is the key to successful rehabilitation. Oromotor therapy is the most useful nonsurgical option. Drugs are unsuitable for long-term use due to adverse effects causing serious medical complications or noncompliance. Botulinum toxin A injection is promising, but no data exists on optimal dosage, duration of action and frequency of repeat injections. Bilateral submandibular duct relocation with bilateral sublingual gland excision has been shown to be effective and safe in long-term follow-up of the largest series of patients. At present, it is the best available surgical option.

Entities:  

Mesh:

Year:  2006        PMID: 17099344     DOI: 10.1097/MOO.0b013e328011014a

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  9 in total

1.  Anatomical localization of submandibular gland for botulinum toxin injection.

Authors:  J H Lee; B N Lee; S O Kwon; R H Chung; S H Han
Journal:  Surg Radiol Anat       Date:  2010-03-11       Impact factor: 1.246

2.  Impact and management of drooling in children with neurological disorders: an Italian Delphi consensus.

Authors:  Antonella Riva; Elisabetta Amadori; Maria Stella Vari; Alberto Spalice; Vincenzo Belcastro; Maurizio Viri; Donatella Capodiferro; Antonino Romeo; Alberto Verrotti; Pasquale Striano
Journal:  Ital J Pediatr       Date:  2022-07-19       Impact factor: 3.288

3.  Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis.

Authors:  João Costa; Maria Luz Rocha; Joaquim Ferreira; Teresinha Evangelista; Miguel Coelho; Mamede de Carvalho
Journal:  J Neurol       Date:  2008-02-19       Impact factor: 4.849

4.  Bilateral submandibular duct relocation by high-frequency radiosurgery.

Authors:  Gábor Katona; Zsuzsa Csákányi; Anikó Lorincz; Imre Gerlinger
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-02-05       Impact factor: 2.503

Review 5.  Sialorrhoea and drooling in patients with Parkinson's disease: epidemiology and management.

Authors:  Marcelo Merello
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

6.  Contemporary surgical management of severe sialorrhea in children.

Authors:  Jeremy Hornibrook; Neil Cochrane
Journal:  ISRN Pediatr       Date:  2012-03-28

7.  Management of drooling for patients in the north of Iran: Analysis of the surgical management.

Authors:  Seyed Ebrahim Naghavi; Mir Mohammad Jalali
Journal:  J Res Med Sci       Date:  2010-01       Impact factor: 1.852

8.  Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience.

Authors:  Davide Zanon; Cristina Tumminelli; Anna Maria Chiara Galimberti; Lucio Torelli; Alessandra Maestro; Egidio Barbi; Natalia Maximova
Journal:  Ital J Pediatr       Date:  2021-11-06       Impact factor: 2.638

9.  Neurologic uses of botulinum neurotoxin type A.

Authors:  John P Ney; Kevin R Joseph
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.